| 1 WOMAC function (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 1 to 4 weeks post‐injection |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
3.00 [‐2.39, 8.39] |
| 1.2 5 to 13 weeks post‐injection |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
‐9.0 [‐14.15, ‐3.85] |
| 2 Flexion (degrees) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 1 to 4 weeks post‐injection |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.90 [‐14.69, 4.89] |
| 2.2 5 to 13 weeks post‐injection |
1 |
40 |
Mean Difference (IV, Fixed, 95% CI) |
‐7.05 [‐15.48, 1.38] |
| 3 Patient global assessment (number of patients good or very good) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 3.1 1 to 4 weeks post‐injection |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.83 [0.47, 1.47] |
| 3.2 5 to 13 weeks post‐injection |
1 |
40 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.88 [1.04, 3.39] |
| 4 Safety: total withdrawals overall |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5 Safety: number of patients withdrawn due to adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 6 Safety: number of patients with local adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 7 Safety: number of patients with systemic adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
